Application Note: WB: 1:500-1:2000. ICC/IF: 1:100-1:500. IHC-P: 1:50-1:200. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
Calculated MW: 384
Form: Liquid
Buffer (with preservative): PBS, 150mM NaCl, 50% Glycerol, 0.02% sodium azide.
Concentration: 1 mg/ml (Please refer to the vial label for the specific concentration.)
Background: Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, Dec 2008]
Uniprot ID: P51587
Antigen Species: Human
Immunogen: A synthesized peptide derived from human BRCA2(Accession P51587), corresponding to amino acid residues E2081-P2107.
Purification: Purified by sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns
Conjugation: Unconjugated
Full Name: BRCA2 DNA repair associated
English
Deutsch
